Was ist die Webseite?

http://www.freseniusmedicalcare.com/

Fresenius Medical Care, Else-Kroener-Str. 1, Bad Homburg (2025)

07/11/2025

At ASN Kidney Week 2025, Fresenius Medical Care presented new real-world evidence linking hemodiafiltration (HDF) to improved outcomes for dialysis patients. The oral presentation, “Hemodiafiltration is associated with reduced risk of cardiovascular and fluid-related hospitalization outcomes” was delivered by researchers from our Global Medical Office and The Renal Research Institute (RRI), a subsidiary of Fresenius Medical Care.

Drawing on data from more than 70,000 dialysis patients treated in Fresenius Medical Care NephroCare Clinics in Europe between 2019 and 2022, the study found that HDF was associated with significantly lower rates of cardiovascular- and fluid-related hospitalizations compared to high-flux hemodialysis. The results showed reductions in both hospital admissions and hospital days.
We thank all who attended the session and joined the discussion on how data-driven insights and innovation are advancing kidney care worldwide.

For more information, check out our website: https://freseniusmedicalcare.com/en-us/asn-2025/?utm_source=social&utm_medium=facebook&utm_campaign=kidneyweek2025&utm_content=asn_2025_07nov2025&utm_term=organic3

We thank the authors of the abstract: Yan Zhang, Anke Winter, Linda Hanna Ficociello, Paola Carioni, Otto Árkossy, Michael Anger, Robert Kossmann, Len Usvyat, and Stefano Stuard 💙

06/11/2025

Fresenius Medical Care was proud to host the breakfast symposium “HighVolumeHDF: The Next Standard of Care for U.S. Patients – Evidence and Practical Use” as part of the ASN Kidney Week 2025 Exhibitor Spotlight series. The session brought together experts to discuss clinical evidence and real-world insights from outside the U.S., showing how hemodiafiltration (HDF) may help improve patient outcomes.

The conversation highlighted growing interest in adopting HighVolumeHDF within the U.S. Panelists also discussed the operational and clinical considerations of implementing HDF in routine practice, emphasizing the importance of collaboration and education.

We were delighted by the energy and engagement from attendees, reflecting a shared commitment to redefining standards of care in nephrology. Visit us at booth # 1815 to learn more about our research, clinical collaborations, and ongoing innovations in kidney care.

For more information, check out our website: https://freseniusmedicalcare.com/en-us/asn-2025/?utm_source=social&utm_medium=facebook&utm_campaign=kidneyweek2025&utm_content=asn_2025_06nov2025&utm_term=organic2

05/11/2025

Let's talk about one of the world’s fastest-growing health challenges affecting many individuals and families: Diabetes.

🌍 1 in 9 adults live with diabetes.
😮 4 in 10 don’t know they have it.

Unmanaged diabetes is the leading cause of kidney failure, a serious condition that can progress silently for years before showing symptoms. But the risks don't stop there. It also increases the chances of other serious health challenges, like heart disease, vision loss, and dementia.

Early detection matters. By acting today, you can make all the difference in protecting your health.

👉 Explore our campaign page for helpful information, practical tips, and a link to the free risk assessment by the International Diabetes Federation: https://freseniusmedicalcare.com/en/media/insights/together/world-diabetes-day-2025/?utm_source=facebook&utm_medium=social&utm_campaign=wdd2025_organicsome

Start your journey to living well today.

04/11/2025

News 📢: This morning, Fresenius Medical Care published its Q3 2025 financial results, further accelerating organic revenue growth and delivering a 28% increase in operating income in the third quarter. Read the full release below.

The results of Q3 2025 underline our ongoing operational and financial progress, as all three operating segments contributed to strong organic revenue growth of 10% at constant currency, and the accelerated operating income drove a step-change in margin expansion to 11.7%.

The FME25+ program continued its positive momentum, delivering EUR 47 million additional sustainable savings. In the first nine months, FME25+ has already delivered EUR 174 million in additional annual savings.

Quote, CEO Helen Giza: “In Q3 of 2025, we continued the momentum and further accelerated revenue growth. Conversion into operating income growth increased as planned for the third consecutive quarter, underlining our continued operational and financial progress. Our Group operating income margin of 11.7% extended well into the implied full year 2025 range of 11% to 12%. This demonstrates important progress on our trajectory to deliver our full year 2025 financial outlook. All three operating segments contributed to the Group organic growth of 10%. U.S. same market treatment growth was slightly positive in Q3. Operating income in Care Enablement grew strongly by 38%, leading to a margin of 7.6%. In parallel, Care Delivery significantly improved profitability, reaching a strong margin of 14.5%, at the top end of its 2025 target margin band.”

Helen Giza added: “We advanced our FME Reignite strategy for value creation with the launch of the first tranche of our initial share buyback program, the ownership increase in our Value-Based Care entity Interwell Health and the continued rollout of the 5008X in the U.S. For 2025, we are well on track to achieve our commitments, while we are excited about what lies ahead with FME Reignite.”

Read more in today’s press release: https://freseniusmedicalcare.com/en/media/newsroom/q3-2025/?utm_source=social&utm_medium=facebook&utm_campaign=financialearnings&utm_content=q3_financial_earnings_05nov2024&utm_term=global

04/11/2025

News 📢: This morning, Fresenius Medical Care published its Q3 2025 financial results, further accelerating organic revenue growth and delivering a 28% increase in operating income in the third quarter. Read the full release below.

The results of Q3 2025 underline our ongoing operational and financial progress, as all three operating segments contributed to strong organic revenue growth of 10% at constant currency, and the accelerated operating income drove a step-change in margin expansion to 11.7%.

The FME25+ program continued its positive momentum, delivering EUR 47 million additional sustainable savings. In the first nine months, FME25+ has already delivered EUR 174 million in additional annual savings.

Quote, CEO Helen Giza: “In Q3 of 2025, we continued the momentum and further accelerated revenue growth. Conversion into operating income growth increased as planned for the third consecutive quarter, underlining our continued operational and financial progress. Our Group operating income margin of 11.7% extended well into the implied full year 2025 range of 11% to 12%. This demonstrates important progress on our trajectory to deliver our full year 2025 financial outlook. All three operating segments contributed to the Group organic growth of 10%. U.S. same market treatment growth was slightly positive in Q3. Operating income in Care Enablement grew strongly by 38%, leading to a margin of 7.6%. In parallel, Care Delivery significantly improved profitability, reaching a strong margin of 14.5%, at the top end of its 2025 target margin band.”

Helen Giza added: “We advanced our FME Reignite strategy for value creation with the launch of the first tranche of our initial share buyback program, the ownership increase in our Value-Based Care entity Interwell Health and the continued rollout of the 5008X in the U.S. For 2025, we are well on track to achieve our commitments, while we are excited about what lies ahead with FME Reignite.”

Read more in today’s press release: https://freseniusmedicalcare.com/en/media/newsroom/q3-2025/?utm_source=social&utm_medium=facebook&utm_campaign=financialearnings&utm_content=q3_financial_earnings_05nov2024&utm_term=global

30/10/2025

Come see us📢: Fresenius Medical Care will showcase new research at ASN Kidney Week 2025, November 5-9 in Houston, highlighting real-world advances in hemodiafiltration (HDF) and artificial intelligence (AI) that are shaping the future of kidney care. Read more in the press release linked below.

Our Global Medical Office will present multiple abstracts exploring how innovation and evidence-based science are improving outcomes for patients and supporting clinicians in daily practice. Among the highlights is our oral presentation showing how HDF is associated with a reduced risk of cardiovascular and fluid-related hospitalizations, and AI-driven studies advancing fall-risk prediction, clinician education, and even safe, personalized diet planning for dialysis patients.

Quote, Dr. Frank Maddux, MD, FACP: “This research reflects Fresenius Medical Care’s commitment to patient-centered innovation, demonstrating how advanced therapies like hemodiafiltration can be tailored to improve outcomes in real-world settings. By applying novel physical principles to kidney replacement therapy, we are leading the field in delivering transformative solutions that elevate the standard of care and advance precision medicine globally.”

For a full overview of key presentations and events at the ASN Kidney Week, read more in today’s press release: https://freseniusmedicalcare.com/en/media/newsroom/asn-kidney-week-2025/?utm_source=facebook&utm_medium=social&utm_campaign=30oct2025_pressrelease_asn

28/10/2025

Fresenius Medical Care and our CEO, Helen Giza, has once again been named on The Women's Edge and The Boston Globe Media’s list of the Top 100 Women-Led Businesses in Massachusetts, ranking fourth overall.

This recognition reflects the strength of our leadership under Helen Giza, CEO and Chair of the Management Board, who continues to drive our hashtag strategy – shaping the company’s innovation and direction in kidney care for the coming years.

We are proud to foster a culture that empowers our teams and builds trust with patients worldwide. Our global Patient Net Promoter Score of 72 highlights that commitment to care and excellence across all settings.

Congratulations to all the incredible women leaders honored on this year’s list – and thank you to The Women’s Edge and The Boston Globe Magazine for championing women in leadership for 25 years.

Read more here: https://freseniusmedicalcare.com/en/media/newsroom/top100-women-led-businesses-in-massachusetts/?utm_source=facebook&utm_medium=social&utm_campaign=28oct2025_fme_100topwomanaward_shortnews

21/10/2025

Last week, during the EDTNA (European Dialysis and Transplant Nurses Association), we celebrated the Nursing Excellence Awards, bringing together more than 200 colleagues from across our network. The evening honored nurses for their remarkable achievements, innovation, and dedication to improving the lives of patients worldwide 🏆🎉

From local country recognitions to corporate awards, the celebration was a moment to reflect on the strength of our nursing community and to reinforce our shared values of quality, compassion, and collaboration.

Swipe through to see photos from the event and join us in celebrating all award recipients for their outstanding contributions to patient care and to the future of nursing 👏

21/10/2025

Mark your calendars! 📅 On November 4th, Fresenius Medical Care will release its Q3 2025 financial results.

to be among the first to read our press release!

Fresenius Medical Care

07/11/2025

06/11/2025

05/11/2025

04/11/2025

04/11/2025

30/10/2025

28/10/2025

21/10/2025

21/10/2025

Adresse

Telefon

Webseite

Benachrichtigungen

Verknüpfungen

Teilen

Kategorie